Amiodarone

Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.

Moderate dual CYP3A4 and CYP2C9 inhibitor may increase macitentan exposure. Avoid co-administration.

Moderate dual CYP3A4 and CYP2C9 inhibitor increases macitentan exposure. Avoid concomitant use.

Co-administration contraindicated due to potential for cardiac arrhythmias.

Concomitant administration can affect conduction and repolarization and is not recommended.

Class III antiarrhythmic; potential to prolong refractoriness. Not recommended as concomitant therapy with sotalol.

Avoid use; may prolong QT interval and increase risk of arrhythmias with anagrelide.

Avoid concomitant use due to QT prolongation risk.

Antiarrhythmic with negative chronotropic properties that may be additive to those of beta-blockers.

Antiarrhythmic with negative chronotropic properties that may be additive to beta-blocker effects, increasing bradycardia risk.

Antiarrhythmic with negative chronotropic properties additive to beta-blocker effects, increasing bradycardia risk.

Antiarrhythmic agent may have additive effects resulting in hypotension and/or marked bradycardia when used concomitantly with beta-adrenergic receptor inhibitors.

As a CYP2C9 inhibitor, amiodarone combined with a strong or moderate CYP3A inhibitor will likely lead to large increases in bosentan plasma concentrations.

CYP2C9 and P-glycoprotein inhibitor increases S(-)-enantiomer concentrations at least 2-fold, enhancing beta-blocking activity and potentially slowing heart rate.

May increase carvedilol levels resulting in further slowing of heart rate or cardiac conduction.

Increased risk of inducing ventricular arrhythmias when used concomitantly with chloroquine.

Antiarrhythmic affected by clarithromycin CYP3A inhibition. Risk of QTc prolongation and arrhythmias.

Increased pulmonary toxicity may result from combined effect with cyclophosphamide.

Increases digoxin serum concentration by 70%. Requires monitoring and dose reduction of 30-50%.

Class III anti-arrhythmic drug that may increase risk of QT prolongation and Torsades de Pointes due to additive effects on heart rate and QT interval.

Do not exceed 10 mg/20 mg ezetimibe and simvastatin tablets daily due to increased myopathy risk.

Amiodarone may increase plasma flecainide levels two-fold or more in some patients, requiring flecainide dosage reduction.

Concomitant administration may increase QT prolongation, particularly with high-dose fluconazole (800 mg). Caution required if concomitant use necessary.

Should be avoided due to risk of QT prolongation and torsades de pointes.

Coadministration may result in serious symptomatic bradycardia. Use is not recommended.

May decrease or increase thyroid hormone secretion, resulting in hypothyroidism or hyperthyroidism; slowly excreted producing prolonged effects.

Cardiac effects may be additive or antagonistic and toxic effects may be additive when administered with lidocaine.

Increases risk of myopathy/rhabdomyolysis when used with HMG-CoA reductase inhibitors like lovastatin.

Both ondansetron and amiodarone prolong the QT interval; used together they raise the risk of QT prolongation and torsades de pointes. Avoid the combination in patients with additional QT risk factors (electrolyte disturbance, bradycardia, other QT-prolonging drugs).

Reduction in exposure to amiodarone and its metabolite observed when coadministered.

Class III anti-arrhythmic; associated with Torsades de Pointes in bradycardia patients. Cardiologist advice recommended if ZEPOSIA treatment considered.

α-adrenergic blocking agent that blocks phenylephrine and is in turn blocked by phenylephrine.

Class III anti-arrhythmic drug associated with Torsades de Pointes in bradycardic patients; should generally not be initiated with PONVORY.

Concomitant administration affects conduction and repolarization and is not recommended.

Increases risk of myopathy and rhabdomyolysis. Do not exceed simvastatin 20 mg daily.

Class III antiarrhythmic associated with Torsades de Pointes in bradycardia patients; should generally not be initiated with siponimod.

Coadministration may result in serious symptomatic bradycardia. Mechanism unknown. Coadministration not recommended; if required, cardiac monitoring is needed.

P-gp inhibitor that increases talazoparib concentrations; avoid coadministration or reduce talazoparib dose and monitor for increased adverse reactions.

Class III antiarrhythmic that prolongs QTc interval. Concomitant use should be avoided due to additive QTc prolongation risk.

CYP1A2 inhibitor antiarrhythmic; concomitant use should be avoided due to potential for hypotension, bradycardia, or excessive drowsiness.

Concomitant use should be avoided due to potential interactions. If clinically necessary, initiate with 2 mg and titrate cautiously.

Should be avoided due to CYP1A2 inhibition. If necessary, initiate tizanidine at 2 mg and titrate cautiously; monitor for hypotension, bradycardia, or excessive drowsiness.

Class III antiarrhythmic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.

CYP2C9 inhibitor that increases warfarin effect and INR; requires close INR monitoring

CYP2C9 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.

P-glycoprotein inhibitor that increases afatinib exposure. Reduce GILOTRIF dose by 10 mg per day if not tolerated.

Amiodarone potentiates cyclophosphamide's pulmonary toxicity when used concomitantly or sequentially.

Increases cyclosporine concentrations. Dosage adjustment essential.

P-gp inhibitor that does not require dosage adjustment of dabigatran etexilate but increases exposure, especially with renal impairment.

Caution advised when using class III antiarrhythmic drugs with ropivacaine; specific interaction trials not performed.

CYP2C9 inhibitor may increase dronabinol systemic exposure and adverse reactions; monitor for increased dronabinol-related effects.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

Class 3 antiarrhythmic known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.

Class 3 antiarrhythmic that prolongs QTc interval; caution advised when used with haloperidol due to risk of QT prolongation.

Negative chronotrope that increases risk of bradycardia with ivabradine. Monitor heart rate.

Class III antiarrhythmic drug; specific interaction studies not performed but caution is advised when used with lidocaine and prilocaine.

When administered with lidocaine, cardiac effects may be additive or antagonistic and toxic effects may be additive.

CYP3A4 substrate whose plasma levels may increase with concomitant metronidazole use. Monitor plasma concentrations.

P-glycoprotein inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.

CYP2C9 inhibitor that may increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and increased glucose monitoring may be required.

Moderate CYP3A4 inhibitor that may increase nimodipine plasma concentration and blood pressure lowering effect. Blood pressure monitoring and dose reduction of nimodipine may be necessary.

α-adrenergic blocking agent that blocks phenylephrine and is blocked by phenylephrine.

Alpha-adrenergic blocking agent blocks phenylephrine and is in turn blocked by phenylephrine.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

May increase phenytoin serum levels; monitoring of phenytoin levels recommended.

CYP2D6 substrate/inhibitor that may increase blood levels and/or toxicity of propranolol.

Amiodarone increases quinidine levels by unknown pharmacokinetic mechanisms.

Increases quinidine levels by pharmacokinetic mechanisms not well understood.

Potent P-gp inhibitor that may increase rimegepant exposure. Avoid another dose within 48 hours when co-administered.

Class III antiarrhythmic drug; specific interaction studies not performed but caution is advised.

Drug that interferes with accumulation of radioiodide by the thyroid. Discontinue 6 months before procedure.

Amiodarone is an inhibitor of CYP2C9 and CYP3A4 likely to substantially increase systemic exposure of terbinafine when concomitantly administered.

As a CYP2C9 and CYP3A4 inhibitor, likely to substantially increase terbinafine systemic exposure similar to fluconazole.

As a CYP2C9 and CYP3A4 inhibitor, amiodarone may substantially increase systemic exposure of terbinafine (Cmax and AUC).

Amiodarone causes peripheral neuropathy and concomitant use with thalidomide can cause additive effect; should be used with caution.

CYP2C9 inhibitor that decreases torsemide clearance and increases plasma concentrations; monitor diuretic effect and blood pressure.

In vitro data of benzodiazepines suggest possible drug interaction with triazolam. Caution recommended.

P-gp inhibitor that does not require dosage adjustment of PRADAXA.